

[Clin Nucl Med](#). 2023 Mar 6. doi: 10.1097/RLU.00000000000004612. Online ahead of print.

Short-Interval, Low-Dose [177Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma

Stuart More ¹, Thurandie Naiker ², Nihaad Jacobs ¹, Ferdinand Oompie ³, Vikas Prasad ⁴

¹ From the Divisions of Nuclear Medicine.

² Radiation Oncology.

³ Diagnostic Radiology, Department of Radiation Medicine, University of Cape Town, Cape Town, South Africa.

⁴ Department of Nuclear Medicine; Universität Ulm, Ulm, Germany.

PMID: 36881610 DOI: [10.1097/RLU.00000000000004612](https://doi.org/10.1097/RLU.00000000000004612)

Abstract

Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [177Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [177Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

LinkOut – more resources

Full Text Sources

[Wolters Kluwer](#)

Miscellaneous

[NCI CPTAC Assay Portal](#)